- Eli Lilly's experimental weight-loss pill, orforglipron, achieved an average 12.4 per cent body weight reduction in patients over 72 weeks, according to a new study.
- The results led to a 14 per cent drop in Lilly's shares, as they fell short of competitor Novo Nordisk's injectable Wegovy, which showed a 14.9 per cent weight loss.
- Orforglipron is a small molecule pill, which is hoped to provide a convenient and pain-free alternative to injectable treatments.
- Lilly plans to file for regulatory approvals before the end of 2025, aiming for the pill to be used for early intervention and long-term weight management.
- While common side effects were mild-to-moderate gastrointestinal issues, the drug also showed benefits in lowering heart disease risk markers.
IN FULL
